DDInter1175 DDInter1676
A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Methotrimeprazine {u} (Compound) resembles {v} (Compound) Moricizine
Methotrimeprazine {u} (Compound) resembles {v} (Compound) Aceprometazine
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Methotrimeprazine {u} (Compound) binds {v} (Gene) ADRA1D
Methotrimeprazine {u} (Compound) upregulates {v} (Gene) CNPY3
Methotrimeprazine {u} (Compound) downregulates {v} (Gene) TXNDC9
Methotrimeprazine {u} (Compound) causes {v} (Side Effect) Urinary retention
Methotrimeprazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Methotrimeprazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Methotrimeprazine (Compound) resembles Moricizine (Compound)
Methotrimeprazine (Compound) resembles Aceprometazine (Compound)
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Methotrimeprazine (Compound) binds ADRA1D (Gene)
Methotrimeprazine (Compound) upregulates CNPY3 (Gene)
Methotrimeprazine (Compound) downregulates TXNDC9 (Gene)
Methotrimeprazine (Compound) causes Urinary retention (Side Effect)
Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate